Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 So You want to be a principal investigatorJournal of Oncology Practice.  14:e384-e392. 2018
2018 Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.Nature Communications.  9:2024. 2018
2018 Ethnicity and breast cancer characteristics in Kenya.Breast Cancer Research and Treatment.  167:425-437. 2018
2017 Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.Blood.  130:2527-2536. 2017
2017 Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Annals of Oncology.  28:2264-2271. 2017
2017 Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.Clinical Cancer Research.  23:3544-3551. 2017
2017 Academic Cancer Center Phase I Program Development.Oncologist.  22:369-374. 2017
2016 Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.Haematologica.  101:1327-1332. 2016
2016 Breast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya.Oncologist.  21:1138-1148. 2016
2016 Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.Cancer Chemotherapy and Pharmacology.  78:509-515. 2016
2016 Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.Annals of Oncology.  27:1041-1047. 2016
2016 A Community-Oriented Approach to Breast Cancer in a Low-Resource Setting: Improving Awareness, Early Detection and Treatment of Breast Cancer in Tajikistan.Breast Journal.  22:330-334. 2016
2015 Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).Cancer Chemotherapy and Pharmacology.  76:949-955. 2015
2015 SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.Clinical Colorectal Cancer.  14:72-80. 2015
2015 EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.Journal of Clinical Oncology.  33:1609-1619. 2015
2014 Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.Journal of Clinical Oncology.  32:3840-3847. 2014
2014 Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.Journal of Clinical Oncology.  32:3619-3625. 2014
2014 Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.Breast.  23:591-596. 2014
2014 A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.Cancer Medicine.  3:988-997. 2014
2014 A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.Annals of Oncology.  25:1416-1421. 2014
2014 A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.Clinical Cancer Research.  20:3581-3588. 2014
2014 Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy.Supportive Care in Cancer.  22:1833-1841. 2014
2014 Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting.Current Medical Research and Opinion.  30:529-536. 2014
2013 Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.Cancer Medicine.  2:925-932. 2013
2013 Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.New England Journal of Medicine.  369:1691-1703. 2013
2013 Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.British Journal of Haematology.  162:693-701. 2013
2013 Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.Clinical Colorectal Cancer.  12:218-222. 2013
2013 Breast cancer diagnosis in a resource poor environment through a collaborative multidisciplinary approach: the Kenyan experience.Journal of Clinical Pathology.  66:307-311. 2013
2013 Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).British Journal of Haematology.  160:538-546. 2013
2013 Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.Blood.  121:537-545. 2013
2013 Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND studyTransfuze a Hematologie Dnes.  19:191. 2013
2012 Therapeutic optimization of aromatase inhibitor-associated arthralgia: Etiology, onset, resolution, and symptom management in early breast cancerCommunity Oncology.  9:94-102. 2012
2012 Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.Clinical Cancer Research.  18:1092-1100. 2012
2011 Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.Journal of Clinical Oncology.  29:3877-3884. 2011
2011 Eltrombopag for chronic immune thrombocytopenia.Lancet.  377:1919. 2011
2011 Abiraterone and increased survival in metastatic prostate cancerNew England Journal of Medicine.  364:1995-2005. 2011
2011 Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.Clinical Breast Cancer.  11:82-92. 2011
2011 Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402))Lancet.  377:640. 2011
2011 Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.Lancet.  377:393-402. 2011
2010 Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerClinical Breast Cancer.  10:281-287. 2010
2010 Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.Clinical Breast Cancer.  10:275-280. 2010
2010 A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.Cancer Investigation.  28:208-215. 2010
2010 Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).Cancer Biotherapy and Radiopharmaceuticals.  25:13-19. 2010
2010 Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancerJournal of Thoracic Oncology.  5:1977-1985. 2010
2009 Analysis of the impact and burden of illness of adult chronic ITP in the US.Current Medical Research and Opinion.  25:2961-2969. 2009
2009 Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.Journal of Clinical Oncology.  27:5023-5030. 2009
2009 A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).Annals of Oncology.  20:1068-1073. 2009
2009 Data-driven medical decision-making in managing chemotherapy-induced nausea and vomitingCommunity Oncology.  6:62-67. 2009
2009 Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: Results from a community oncology practiceCommunity Oncology.  6:257-261. 2009
2007 Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.Clinical lymphoma.  8 Suppl 1:S13-S17. 2007
2007 Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.Investigational New Drugs.  25:565-570. 2007
2007 Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.New England Journal of Medicine.  357:2237-2247. 2007
2007 Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.Journal of Clinical Oncology.  25:669-674. 2007
2006 Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.Journal of Clinical Oncology.  24:2456-2464. 2006
2005 Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.Journal of Clinical Oncology.  23:9089-9096. 2005
2005 Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.Prostate.  65:316-321. 2005
2004 Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.British Journal of Haematology.  125:470-476. 2004
2004 Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.Journal of Clinical Oncology.  22:1063-1070. 2004
2003 Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story.Journal of the Medical Association of Georgia.  92:39-46. 2003
2002 A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.Clinical Cancer Research.  8:3092-3099. 2002
2002 Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.Journal of Clinical Oncology.  20:3262-3269. 2002
2002 Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.Blood.  99:4336-4342. 2002
2002 Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.Seminars in Oncology.  29:87-92. 2002
2001 Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.Journal of Clinical Oncology.  19:3918-3928. 2001
2001 Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.Journal of Clinical Oncology.  19:3234-3243. 2001
2001 A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.Cancer Biotherapy and Radiopharmaceuticals.  16:125-132. 2001
2001 Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.Annals of Oncology.  12:109-114. 2001
2000 A pilot study of anti-cd20 moab mtuximab in patients with refractory immune thrombocytopenic purpura (TTP)Blood.  96. 2000
2000 BR96-doxorubicin: Been there, done that! [1] (multiple letters)Journal of Clinical Oncology.  18:4000. 2000
2000 Oral chlorambucil and prednisone with rituximab as initial chemotherapy for low grade non hodgkin's lymphoma: a phase ii trialBlood.  96. 2000
2000 Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.Journal of Clinical Oncology.  18:2282-2292. 2000
2000 Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomasJournal of Clinical Oncology.  18:1316-1323. 2000
1999 Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.Cancer Biotherapy and Radiopharmaceuticals.  14:451-463. 1999
1999 Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.Clinical Cancer Research.  5:2330-2337. 1999
1999 NCCN practice guidelines for Hodgkin's disease. National Comprehensive Cancer Network.Oncology.  13:78-110. 1999
1999 Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.Journal of Clinical Oncology.  17:478-484. 1999
1999 Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.Journal of Clinical Oncology.  17:268-276. 1999
1998 Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease.Journal of Immunotherapy.  21:379-388. 1998
1998 Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.Journal of The American Academy of Dermatology.  39:63-73. 1998
1998 Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy.Stain technology.  73:186-197. 1998
1998 Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.Blood.  91:399-405. 1998
1998 Diphtheria toxin fusion proteins.Current Topics in Microbiology and Immunology.  234:63-81. 1998
1997 Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.Cancer Biotherapy and Radiopharmaceuticals.  12:79-87. 1997
1997 A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow.Human Gene Therapy.  8:157-170. 1997
1996 Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.  19:206-217. 1996
1995 Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.  18:231-241. 1995
1995 Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.Cancer Research.  55:4339-4346. 1995
1995 CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.Blood.  85:2910-2917. 1995
1993 A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.Cancer Research.  53:4555-4562. 1993
1993 Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.Journal of Immunology.  151:3390-3398. 1993
1992 Monoclonal antibody therapy of cancer.Critical Reviews in Oncology/Hematology.  13:271-282. 1992
1992 Advances in monoclonal antibody therapy of cancer.American Journal of the Medical Sciences.  304:214-224. 1992
1992 Selection of platelets for refractory patients by HLA matching and prospective crossmatching.Transfusion.  32:633-640. 1992
1992 Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.Cancer Research.  52:4342-4347. 1992
1992 Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody.Journal of Clinical Immunology.  12:116-121. 1992
1992 Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.Journal of Nuclear Medicine.  33:23-29. 1992
1992 Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.Human antibodies and hybridomas.  3:19-24. 1992
1991 Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.Cancer Research.  51:5461-5466. 1991
1991 Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.Cancer Research.  51:4155-4163. 1991
1991 Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody.Journal of Nuclear Medicine.  32:1162-1168. 1991
1991 In-111 labeled monoclonal anti-carcinoembryonic antigen antibody (ZCE025) in the immunoscintigraphic imaging of metastatic antigen-producing adenocarcinomas.Clinical Nuclear Medicine.  16:110-116. 1991
1990 Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia.Arthritis and Rheumatism.  33:1233-1239. 1990
1990 Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans.Journal of biological response modifiers.  9:178-184. 1990
1990 A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data.Cancer Immunology, Immunotherapy.  32:185-190. 1990
1989 Monocyte-platelet interaction in immune and nonimmune thrombocytopenia.Blood.  74:1328-1331. 1989
1989 Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia.Blood.  73:662-665. 1989
1989 Quinidine-induced immune thrombocytopenia.Henry Ford Hospital medical journal.  37:28-32. 1989
1988 Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects.JNCI: Journal of the National Cancer Institute.  80:932-936. 1988
1988 Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response.JNCI: Journal of the National Cancer Institute.  80:937-942. 1988
1988 Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma.Journal of Clinical Oncology.  6:1059-1065. 1988
1988 Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets.British Journal of Haematology.  68:47-51. 1988
1987 Immune thrombocytopenia: effects of maternal gamma globulin infusion on maternal and fetal serum, platelet, and monocyte IgG.American Journal of the Medical Sciences.  293:112-118. 1987
1987 Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia.Blood.  69:278-283. 1987
1986 In vitro effects of gammaglobulin (IgG) on human monocyte Fc receptor function. I. Effect on monocyte membrane-associated IgG and Fc receptor-dependent binding of antibody-coated platelets.American Journal of Hematology.  23:197-207. 1986
1986 Phase I clinical trial of CO17-1A monoclonal antibody.Hybridoma.  5 Suppl 1:S117-S123. 1986

Chapter

Year Title Altmetric
2013 CDX-011 (Glembatumumab vedotin, CR011-vcMMAE).  211-220. 2013

Principal Investigator On

  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by ROCHE TCRC, INC. 2018 - 2023
  • Private Grant  awarded by Sanofi US Services Inc 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2018 - 2023
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2022
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017 - 2022
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant - Early Phase Clinical Research  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Private Grant  awarded by ELI LILLY AND COMPANY 2015 - 2020
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC. 2015 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2018 - 2020
  • Private Grant  awarded by Sanofi US Services Inc 2018 - 2020
  • Private Grant  awarded by AILERON THERAPEUTICS 2015 - 2020
  • School of Medicine Clinical Investigator Training Program  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2016 - 2018
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Support Participation in the Experimental Therapeutics Clinical Trials Network (ETCTN)  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Early Phase Clinical Research  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC--T) as Adjuvant Treatment of Operable Breast Cancer HER2Neu Negative Patients with Positive Axillary Lymph Nodes  awarded by BREAST CANCER INTERNATIONAL RESEARCH GROUP 2001 - 2011
  • Investigator On

  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by ABBVIE INC 2018 - 2023
  • Private Grant  awarded by MINNEAMRITA THERAPEUTICS, LLC 2018 - 2023
  • Private Grant  awarded by SYROS PHARMACEUTICALS INC. 2018 - 2023
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2023
  • Private Grant  awarded by DECIPHERA PHARMACEUTICALS. LLC 2018 - 2023
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017 - 2022
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2022
  • Private Grant  awarded by FORTY SEVEN, INC. 2018 - 2022
  • Private Grant  awarded by FORTY SEVEN, INC. 2017 - 2022
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2017 - 2022
  • Private Grant  awarded by AFFIMED GMBH 2016 - 2021
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2016 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Overcoming PAAP Inhibitor Resistance of BACA-Deficient Ovarian Cancers  awarded by DOD - Department of Defense 2018 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2021
  • Private Grant  awarded by CELSION CORPORATION 2015 - 2020
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2015 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by Genentech 2015 - 2020
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • Private Grant  awarded by KALA PHARMACEUTICALS, INC. 2016 - 2018
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2014 - 2018
  • Private Grant  awarded by HEAT BIOLOGICS 2015 - 2017
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016
  • Private Grant  awarded by AILERON THERAPEUTICS 2015
  • Education And Training

  • Doctor of Medicine, Heidelberg University
  • Full Name

  • Mansoor Saleh
  • Blazerid

  • mns